12
Participants
Start Date
March 25, 2024
Primary Completion Date
March 22, 2026
Study Completion Date
March 22, 2026
Tuvusertib [14C]Tuvusertib microtracer
Participants will receive single oral dose of Tuvusertib containing a \[14C\] Tuvusertib microtracer solution on Day 1 of period 1 under fasted conditions.
Tuvusertib
Participants will also receive a single oral dose of Tuvusertib on Day 1 of Period 1 or Period 1a, and daily single oral dose of Tuvusertib for 2 weeks in 21 days cycle of Period 2.
Tuvusertib + [14C]Tuvusertib microdose bolus injection
In Period 1a, participants will receive on Day 1 of Period 1 a single oral dose of tuvusertib and an intravenous (IV) (14C) tuvusertib microdose as bolus injection.
Pharmaceutical Research Associates Magyarország Kutatás - Fejlesztési Kft., Klinikai Farmakológiai Vizsgálóhely, Budapest
Észak Pesti Centrum Kórház-Honvédkórház, Onkológiai Osztály, Budapest
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY